New Oxygen (SY.US) announced results for the fourth quarter of 2023 and full-year financial results on Wednesday.
The Zhitong Finance App learned that New Oxygen (SY.US) announced results for the fourth quarter of 2023 and financial results for the full year on Wednesday. According to the data, New Oxygen's total revenue for the fourth quarter was RMB 391 million (approximately US$55 million), and the same period in 2022 was RMB 325 million, up about 20% year-on-year, better than market expectations. Earnings per share for the fourth quarter were 0.03 US dollars, better than market expectations.
In the fourth quarter, information services and other revenue was RMB 268 million (approximately US$37.8 million), compared to RMB 232 million for the same period in 2022, an increase of 15.8% year-on-year, mainly due to the increase in “New Oxygen Premium” revenue.
Revenue from reservation services was RMB 20.6 million (approximately US$2.9 million), compared to RMB 26 million in the same period in 2022, down 20.7% year-on-year, mainly due to operational strategies providing higher subsidies to end users.
Revenue from medical product sales and maintenance services was RMB 102 million (approximately US$14.4 million), compared to RMB 67.7 million in the same period in 2022, an increase of 50.6% year-on-year, mainly due to increased sales of injectable beauty products.
In addition, New Oxygen's moving average MAU (monthly active users) for the fourth quarter was 2.7 million, compared to 4 million in the same period in 2022; the number of medical service providers that ordered the information search platform was 1,289, compared to 1,489 in the same period in 2022. The total number of users who purchased through the reservation service was 139,000, and the total number of medical and aesthetic transactions facilitated through the New Oxygen Platform was RMB 470.9 million.
As of press release, New Oxygen fell 0.96% to $1.03.